Table 1. Baseline Characteristics of patients.
| Characteristics of patients: | Allogeneic myeloablative N(%) |
Allogeneic NMA/RIC N(%) |
Autologous N(%) |
|---|---|---|---|
| Number of patients | 34 | 16 | 97 |
| Number of centers | 24 | 12 | 53 |
| Age, median (range), years | 47 (27-60) | 49 (24-62) | 56 (32-74) |
| Age at transplant, years | |||
| 20-29 | 1 (3) | 1 (6) | 0 |
| 30-39 | 7 (21) | 0 | 8 (8) |
| 40-49 | 16 (47) | 8 (50) | 17 (18) |
| 50-59 | 9 (26) | 5 (31) | 41 (42) |
| 60-69 | 1 (3) | 2 (13) | 28 (29) |
| >=70 | 0 | 0 | 3 (3) |
| Male Sex | 18 (53) | 5 (31) | 62 (64) |
| Karnofsky score>=90% | 18 (53) | 8 (50) | 57 (59) |
| Non Caucasian | 8 (24) | 4 (25) | 27 (28) |
| Immunochemical subtype | |||
| IgG | 13 (38) | 7 (44) | 54 (56) |
| IgA | 5 (15) | 0 | 13 (13) |
| Light chain | 8 (24) | 6 (38) | 16 (16) |
| Non-secretory/others | 8 (24) | 3 (19) | 14 (14) |
| Albumin<=3.5 at diagnosis, g/dL | 9 (26) | 4 (25) | 36 (37) |
| Hemoglobin <10at diagnosis, mg/dL | 20 (59) | 9 (56) | 39 (40) |
| Disease status prior to transplant | |||
| Complete remission | 6 (18) | 3 (19) | 19 (20) |
| Partial remission | 16 (47) | 7 (44) | 54 (56) |
| Minimal response/Stable disease | 3 (9) | 4 (25) | 14 (14) |
| Relapse/Progression | 3 (9) | 1 (6) | 1 (1) |
| Missing | 6 (18) | 1 (6) | 9 (9) |
| Lines of chemotherapy pretransplant | |||
| 1 | 19(56) | 7(44) | 57 (59) |
| 2 | 10 (29) | 3 (19) | 21 (22) |
| >2 | 4 (12) | 3 (19) | 12 (12) |
| Induction therapy | |||
| Melphalan-Prednisone ±others | 4 (12) | 3 (19) | 2 (2) |
| VAD | 13 (38) | 4 (25) | 45 (46) |
| Cyclophosphamide ± others | 6 (18) | 1 (6) | 32 (33) |
| Corticosteroids±others | 8 (24) | 2 (13) | 9 (9) |
| Others | 3 (9) | 6 (38) | 9 (9) |
| Thalidomide given as part of lines of therapy | |||
| Yes | 2 (6) | 4 (25) | 24 (25) |
| Bortezomib given as part of lines of therapy | |||
| Yes | 2 (6) | 0 | 5 (5) |
| Conditioning regimen | |||
| Melphalan alone | 6 (18) | 4 (25) | 54 (56) |
| Melphalan+TBI+-others | 4 (12) | 0 | 11 (11) |
| Melphalan based no TBI | 6 (18) | 5 (31) | 23 (24) |
| TBI based- No melphalan | 11 (32) | 3 (19) | 0 |
| Busulfan+cyclophosphamide+-others | 6 (18) | 0 | 6 (6) |
| Others | 1 (3) | 4 (25) | 3 (3) |
| Time from diagnosis to transplant, median (range) | 6 (2-13) | 7 (3-16) | 7 (3-18) |
| Time from diagnosis to transplant | |||
| < 6 months | 15 (44) | 6 (38) | 29 (30) |
| 6 - 12 months | 17 (50) | 8 (50) | 58 (60) |
| 12 - 18 months | 2 (6) | 2 (13) | 10 (10) |
| Second transplant | |||
| Auto+auto | 0 | 0 | 25 (26) |
| Auto+allo | 0 | 0 | 4 (4) |
| Type of donor | |||
| HLA-identical | 26 (76) | 12 (75) | NA |
| Identical twin | 1 (3) | 0 | |
| Other related | 2 (6) | 2 (13) | |
| Unrelated | 5 (15) | 2 (13) | |
| Year of transplant | |||
| 1995-1996 | 6 (18) | 1 (6) | 6 (6) |
| 1997-1998 | 4 (12) | 0 | 13 (13) |
| 1999-2000 | 3 (9) | 1 (6) | 16 (16) |
| 2001-2002 | 11 (32) | 7 (44) | 10 (10) |
| 2003-2004 | 3 (9) | 6 (38) | 16 (16) |
| 2005-2006 | 7 (21) | 1 (6) | 36 (37) |
| Median follow-up of recipients, months | 52 (3 - 81) | 30 (18 - 59) | 38 (3 - 149) |
*
Conditioning regimen:
-
Myeloablative:
- CY+TBI (TBI dose> 500 cGy single dose or TBI dose> 800 cGy fractionated) (n=11)
- TBI dose ≥ 500 cGy single dose or TBI dose >800 cGy fractionated) (n=4)
- Busulfan+cyclophosphamide (n=10)
- Busulfan dose > 9 mg/kg (n=1)
- Melphalan dose > 150 mg/m2 (n=8)
-
Non-myeloablative (NMA):
- Fludarabine + cyclophosphamide (n=1)
- TBI=200 cGy (n=1)
- Fludarabine+TBI=200cGY (n=2)
-
Reduced-intensity (RIC):
- Melphalan <=150 mg/mˆ2 (n=8)
- Busulfan<=9 mg/kg (n=2)
- Not specified (n=2)